Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from LLY

Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption'

Health and Human Services Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program, describing the system as fundamentally broken and failing its intended purpose.

Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China

Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY) Zepbound from flooding the market.

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Friday recommending Eli Lilly and Co.’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers.

Earnings Preview: What to Expect From Eli Lilly's Report

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit growth.

Ozempic, Mounjaro Users Cut $6.5 Billion From Grocery Bills: GLP-1 Boom Triggers Panic In Packaged Food Aisles

GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs fundamentally altering consumer food purchasing patterns across America’s retail landscape.

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to “benefit” from the levies.

inkl

Read news from The Economist, FT, and more,
with one subscription

Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season

Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season

These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:LLY) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its…

Eli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell a Different Story

Eli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell a Different Story

Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term upside.

A $1.3 Billion Reason to Buy Eli Lilly Stock Now

A $1.3 Billion Reason to Buy Eli Lilly Stock Now

Eli Lilly has just acquired gene-editing company Verve Therapeutics.

Could Meta and Eli Lilly Trigger the Next Stock Split Boom?

Could Meta and Eli Lilly Trigger the Next Stock Split Boom?

Meta Platforms and Eli Lilly are two stocks that could perform stock splits down the road, and it's not just because of their high share prices.

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.

Get all your
news in one place.

100's of premium titles.
One news app.

Is Eli Lilly and Company Stock Underperforming the Dow?

While Eli Lilly has underperformed the Dow over the past year, analysts remain bullish about the stock’s prospects.

3 Trades Members of Congress Are Making Right Now

Knowing what Congressional leaders are buying can give investors insight into future legislation that could benefit these companies

This Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug Prices

Despite Trump’s executive order to cut drug prices, Eli Lilly’s stock surged, showing strong resilience and impressive gains amidst regulatory concerns.

Are Wall Street Analysts Bullish on Eli Lilly Stock?

Despite lagging behind the broader market over the past year, Eli Lilly continues to enjoy a highly bullish outlook from Wall Street analysts, who remain confident in the company’s long-term growth potential.

Get all your
news in one place.

100's of premium titles.
One news app.

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY

Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients.

Eli Lilly's Quarterly Earnings Preview: What You Need to Know

Eli Lilly is scheduled to report its first-quarter results next month, and analysts expect a significant double-digit earnings growth.

Analysts Love These 2 Stocks to Buy for Q2

Investors could snag these two stocks as BofA flags the companies as well-positioned winners in an uncertain quarter.

Is Eli Lilly Stock Outperforming the Nasdaq?

Eli Lilly has outperformed the Nasdaq over the past year, and analysts are highly optimistic about the stock’s prospects.

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

3 Pharmaceutical Stocks Betting Big on Weight Loss Drugs

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

1 … 6 7 8 9

People

194,068 stories

Robert F. Kennedy Jr

Marjorie Taylor Greene

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Johnson & Johnson (

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Executive Order

Alzheimer Disease

Places

382,119 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play